Last reviewed · How we verify
Tacrolimus &entecavir
This combination uses tacrolimus to suppress immune rejection and entecavir to inhibit hepatitis B virus reverse transcriptase.
This combination uses tacrolimus to suppress immune rejection and entecavir to inhibit hepatitis B virus reverse transcriptase. Used for Organ transplant recipients with chronic hepatitis B infection.
At a glance
| Generic name | Tacrolimus &entecavir |
|---|---|
| Also known as | FK506,Prograf, baraclude |
| Sponsor | Guangdong Provincial People's Hospital |
| Drug class | Combination immunosuppressant and antiviral |
| Target | Calcineurin (tacrolimus); Hepatitis B virus reverse transcriptase (entecavir) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Virology |
| Phase | FDA-approved |
Mechanism of action
Tacrolimus is a calcineurin inhibitor that prevents T-cell activation and proliferation, commonly used in transplant recipients to prevent organ rejection. Entecavir is a nucleoside reverse transcriptase inhibitor that blocks hepatitis B virus replication. This combination addresses both immunosuppression needs and chronic hepatitis B infection in transplant patients.
Approved indications
- Organ transplant recipients with chronic hepatitis B infection
Common side effects
- Nephrotoxicity
- Neurotoxicity
- Hyperglycemia
- Hypertension
- Headache
- Lactic acidosis (entecavir-related)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tacrolimus &entecavir CI brief — competitive landscape report
- Tacrolimus &entecavir updates RSS · CI watch RSS
- Guangdong Provincial People's Hospital portfolio CI